TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16783607

Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: MTHFR A1298C polymorphism
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 1840
Study: 12545290

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg twice a day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11013502

Group type: EXPERIMENTAL
Intervention: Functional restoration program (39 hours per week for 3 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Outpatient intensive physical training (1.5 hours three times per week for 8 weeks)
Number of subjects: 99
Study: 8872871

Group type: EXPERIMENTAL
Intervention: IV 0.5 mg scopolamine (SCO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 35
Study: 1613528

Group type: EXPERIMENTAL
Intervention: Compression ultrasound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Venography
Number of subjects: 60
Study: 6427609

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg) four times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10
Study: 31454347

Group type: EXPERIMENTAL
Intervention: Integration of a preventive nutrition package including age-appropriate behavior change communication (BCC) and small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 2318
Study: 29548623

Group type: EXPERIMENTAL
Intervention: RUSF-v (fortified with arginine and citrulline, daily chloroquine 3 mg/kg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: RUSF-b (basic formulation, weekly chloroquine 150 mg or 225 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both RUSF interventions pooled
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (baseline and washout periods)
Number of subjects: 119
Study: 26283011

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization using the 180‐W GreenLight GL‐XPS
Number of subjects: 281

Group type: COMPARATOR
Intervention: Conventional (monopolar or bipolar) TURP
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Both GL‐XPS and TURP
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Overactive Bladder Questionnaire Short Form
Number of subjects: 281
Study: 24825872

Group type: EXPERIMENTAL
Intervention: Sonication method for diagnosis of catheter-related infections
Number of subjects: 975

Group type: COMPARATOR
Intervention: Semiquantitative roll‐plate culture technique (SQC)
Number of subjects: 975
Study: 22762844

Group type: EXPERIMENTAL
Intervention: Edaravone 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg (single dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edaravone 60 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg (repeated dosing)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 20164395

Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation (HFS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 22
Study: 18058736

Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 10

Group type: COMPARATOR
Intervention: Octreotide (OCTR-LAR)
Number of subjects: 10
Study: 15044407

Group type: EXPERIMENTAL
Intervention: Salpingotomy without suturing (group I; n = 43)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Salpingotomy with suturing (group II; n = 32)
Number of subjects: 97
Study: 11120927

Group type: EXPERIMENTAL
Intervention: Maternal viral RNA levels >43,000 copies/mL
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Maternal cervical HIV-1 DNA
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Vaginal HIV-1 DNA
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Cervical or vaginal ulcers
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Mastitis
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Breast abscess
Number of subjects: 279
Study: 9834048

Group type: EXPERIMENTAL
Intervention: 10 mg zaleplon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg zaleplon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8135430

Group type: EXPERIMENTAL
Intervention: Saphenous cutdown
Number of subjects: 78

Group type: COMPARATOR
Intervention: Percutaneous femoral line
Number of subjects: 78
Study: 2678768

Group type: EXPERIMENTAL
Intervention: Cefonicid 3.5‐5.0 hours preoperatively
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cefonicid 0.5‐1.0 hour preoperatively
Number of subjects: 202

Group type: COMPARATOR
Intervention: Cefoxitin (5 doses beginning 0.5‐1.0 hour preoperatively)
Number of subjects: 202
Study: 264441

Group type: EXPERIMENTAL
Intervention: Fixed appliances
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Removal plates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Functional orthodontics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 31574343

Group type: EXPERIMENTAL
Intervention: Licorice syrup (5 cc, twice a day for 6 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo syrup (5 cc, twice a day for 6 months)
Number of subjects: 39
Study: 30612487

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for insomnia (CBTi)
Number of subjects: 24
Study: 28170357

Group type: EXPERIMENTAL
Intervention: Lower INR goal of 1.5-2.0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard INR goal of 2.5 (range, 2-3)
Number of subjects: 0
Study: 26924011

Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Early oral feeding plus domperidone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional schedule
Number of subjects: 120
Study: 25140981

Group type: EXPERIMENTAL
Intervention: Alcohol use in the last year
Number of subjects: 309

Group type: COMPARATOR
Intervention: Patients who stopped using alcohol in the past year
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Patients with last-year alcohol use and past alcohol use disorders
Number of subjects: 309

Group type: COMPARATOR
Intervention: Patients who stopped using alcohol for at least a year
Number of subjects: 309
Study: 22476610

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19742431

Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive therapies
Number of subjects: 0
Study: 17617280

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg + valsartan 320 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 3161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + valsartan 160 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + valsartan 320 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Valsartan 20 mg
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Amlodipine monotherapy
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Valsartan monotherapy
Number of subjects: 3161
Study: 14707154

Group type: COMPARATOR
Intervention: Typical American control diet with higher sodium intake (150 mmol/d)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Typical American control diet with lower sodium intake (50 mmol/d)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: DASH diet with higher sodium intake (150 mmol/d)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: DASH diet with lower sodium intake (50 mmol/d)
Number of subjects: 390
Study: 12611200

Group type: EXPERIMENTAL
Intervention: Oxomemazine with guaifenesin (T)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Clobutinol (S)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both medicines
Number of subjects: 130
Study: 10221355

Group type: EXPERIMENTAL
Intervention: Visual analogue scales (VAS) of alertness
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Average mood scores
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adaptive tracking
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Body sway
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EEG beta2-amplitudes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Smooth pursuit, DSST, and other EEG-amplitudes
Number of subjects: 9
Study: 7759712

Group type: EXPERIMENTAL
Intervention: Anodal biphasic shocks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cathodal biphasic shocks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both configurations
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cathodal configuration
Number of subjects: 15
Study: 2155881

Group type: EXPERIMENTAL
Intervention: Experimental program consisting of patient teaching via pamphlet and videotape, and regular home visits by a community health nurse.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 6260260

Group type: EXPERIMENTAL
Intervention: 1 MRC unit of pCT in glycine vehicle
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 160 units of pCT in gelatine vehicle
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31764804

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine treatment group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Western medicine treatment group
Number of subjects: 148
Study: 29077816

Group type: EXPERIMENTAL
Intervention: Chewing gum (chlorophyll flavour, with 2.1 g carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no gum chewing)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 25924880

Group type: EXPERIMENTAL
Intervention: Smokers (SMK)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonsmokers (N‐SMK)
Number of subjects: 22
Study: 24580384

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided identification of landmarks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Manual palpation of landmarks
Number of subjects: 170
Study: 22530879

Group type: EXPERIMENTAL
Intervention: Glucose drink (1.0 g·kg(‐1) body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncaloric Sucralose sweetened control drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (EXR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary (SED) activity
Number of subjects: 0
Study: 19304119

Group type: EXPERIMENTAL
Intervention: 5 mg/day enalapril plus 80 mg/day valsartan (combination group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mg/day enalapril (control group)
Number of subjects: 20
Study: 17805035

Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax) administered for at least 6 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax)
Number of subjects: 15
Study: 15657405

Group type: EXPERIMENTAL
Intervention: Individualized dosing of docetaxel (mean 58.1 mg/m2, range 37.4 to 76.4 mg/m2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: BSA-based dosing of docetaxel (60 mg/m2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Individualized dosing of docetaxel
Number of subjects: 59

Group type: COMPARATOR
Intervention: BSA-based dosing of docetaxel
Number of subjects: 59
Study: 11959402

Group type: EXPERIMENTAL
Intervention: At-risk group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 9619472

Group type: EXPERIMENTAL
Intervention: Exercise, education, and stress management (EXESM; n = 29)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Education and stress management (ESM; n = 25)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Waiting list (WL; n = 25)
Number of subjects: 79
Study: 7622809

Group type: EXPERIMENTAL
Intervention: Citalopram (20-60 mg)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 1974072

Group type: EXPERIMENTAL
Intervention: Alpidem 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpidem 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam 2 mg (verum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 433668

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study: 31928032

Group type: EXPERIMENTAL
Intervention: Vignette responses regarding hiring a health care advocate
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Vignette responses regarding hiring a health care advocate for parents
Number of subjects: 1862
Study: 30967159

Group type: EXPERIMENTAL
Intervention: Saline plus sodium hyaluronate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 56
Study: 26439722

Group type: EXPERIMENTAL
Intervention: Co-ingestion of dairy milk with bread
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Co-ingestion of soy milk with bread
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preloading (30 min prior to bread) with either dairy or soy milk
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference meal (white wheat bread with water)
Number of subjects: 12
Study: 25947329

Group type: EXPERIMENTAL
Intervention: LMWH enoxaparin 40 mg subcutaneously once daily plus standard pregnancy surveillance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pregnancy surveillance alone
Number of subjects: 0
Study: 23391727

Group type: EXPERIMENTAL
Intervention: Behavioural activation (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (TAU, antidepressant medication) (n = 50)
Number of subjects: 100
Study: 20682020

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and Tacrolimus (Tac)
Number of subjects: 106
Study: 19766640

Group type: EXPERIMENTAL
Intervention: Delayed-release mesalamine 4.8 g/day
Number of subjects: 772

Group type: COMPARATOR
Intervention: Delayed-release mesalamine 2.4 g/day
Number of subjects: 772
Study: 17320345

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 16494585

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Placebo (COX-2 inhibitors)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (COX-2 inhibitors)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg (COX-2 inhibitors)
Number of subjects: 1429
Study: 12916644

Group type: EXPERIMENTAL
Intervention: Grouping on the left side of the display
Number of subjects: 8

Group type: COMPARATOR
Intervention: Empty left page (control)
Number of subjects: 8
Study: 11180418

Group type: EXPERIMENTAL
Intervention: Court appointed expert siding with the plaintiff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Court appointed expert siding with the defendant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical testimony provided by experts hired by each side (plaintiff and defendant)
Number of subjects: 0
Study: 8815124

Group type: EXPERIMENTAL
Intervention: Plaque reduction assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay-based neutralization assay
Number of subjects: 0
Study: 1510237

Group type: EXPERIMENTAL
Intervention: Cat extracts (active IT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dog extracts (active IT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 24
Study: 6145639

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (PGE2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin (Oxy)
Number of subjects: 200
Study: 29132179

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: nHFT
Number of subjects: 24
Study: 28605119

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage three times per week for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 46
Study: 25496023

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate daily for 4 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (1 pearl per day for 4 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (no supplementation)
Number of subjects: 31
Study: 23127418

Group type: EXPERIMENTAL
Intervention: Cheating condition (language focused on the action: 'Please don't cheat')
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cheater condition (language highlighting implications for identity: 'Please don't be a cheater')
Number of subjects: 3
Study: 21809148

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg bolus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study: 18507542

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 16882622

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with a mean dose of 32 Gy (range 30 - 46 Gy)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with doses of 35 - 46 Gy
Number of subjects: 46
Study: 15310395

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid training course
Number of subjects: 301

Group type: COMPARATOR
Intervention: Wait-listed group
Number of subjects: 301
Study: 11329782

Group type: EXPERIMENTAL
Intervention: Amrubicin 30 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amrubicin 60 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amrubicin 90 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amrubicin 120 mg/day
Number of subjects: 63
Study: 9042095

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris patients
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Female patients with stable angina pectoris
Number of subjects: 809

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 809
Study: 8302687

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule (reference)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral solution under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral solution mixed with orange juice
Number of subjects: 24
Study: 3090588

Group type: EXPERIMENTAL
Intervention: beta blocker (atenolol or propranolol)
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 31695136

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sildenafil citrate (SC)
Number of subjects: 100
Study: 28474088

Group type: EXPERIMENTAL
Intervention: 10 mg IV dexamethasone
Number of subjects: 108

Group type: COMPARATOR
Intervention: IV isotonic saline
Number of subjects: 108
Study: 27321368

Group type: EXPERIMENTAL
Intervention: 1.5 g ACCS100 daily for 3 months
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 3 g ACCS100 daily for 3 months
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 24730717

Group type: EXPERIMENTAL
Intervention: Low-dose lithium carbonate for 4 years
Number of subjects: 19

Group type: COMPARATOR
Intervention: Matched controls (n = 7)
Number of subjects: 19
Study: 20363158

Group type: EXPERIMENTAL
Intervention: Wrist extension splint (Group I, 24 elbows)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Counterforce forearm strap (Group II, 20 elbows)
Number of subjects: 42
Study: 17367559

Group type: EXPERIMENTAL
Intervention: Endoscopic radical antrectomy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Classical endoscopic middle meatal antrostomy
Number of subjects: 119
Study: 16402607

Group type: EXPERIMENTAL
Intervention: Age induced alterations in heart rate dynamics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging relative dynamic dominance of the parasympathetic nervous system function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed concept of 'autonomic aging'
Number of subjects: 0
Study: 12874694

Group type: EXPERIMENTAL
Intervention: Two-port laparoscopic cholecystectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy
Number of subjects: 120
Study: 10801752

Group type: EXPERIMENTAL
Intervention: Early stable ST-segment recovery (50% ST-segment recovery sustained for >4 hours with <100 microV change in the peak lead)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Time to stable ST-segment recovery
Number of subjects: 134
Study: 8846930

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta Estradiol (Estraderm TTS 100 plasters) for 24 weeks, with Chlormadinon 2 mg from day 16 to 28 of the fourth cycle
Number of subjects: 25
Study: 1298792

Group type: EXPERIMENTAL
Intervention: Step-back/ultrasound preparation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Step-back preparation
Number of subjects: 34
Study: 6375802

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g intravenous injection)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (no cefuroxime)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control
Number of subjects: 160